Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.

about

Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.

Item

http://www.wikidata.org/entity/Q55001265

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.

@en

Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.

@nl

type

Item

label

Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.

@en

Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.

@nl

prefLabel

Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.

@en

Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.

@nl

P1476

Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.

@en

P2093

Constantin A Dasanu

http://www.w3.org/2001/XMLSchema#string

Henry Tsai

http://www.w3.org/2001/XMLSchema#string

Michael Del Rosario

http://www.w3.org/2001/XMLSchema#string

P2860

A method for estimating the probability of adverse drug reactions

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

The myeloproliferative disorders.

Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi(®)).

New mutations and pathogenesis of myeloproliferative neoplasms.

P304

226-228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155217697488

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28436280

http://www.w3.org/2001/XMLSchema#string